Form D · Biotechnology
Cyprotex PLC
Manchester, X0 · CIK 0001499299
Offering snapshot reported Aug 17, 2010 · SEC filing
- Reported sold
- $2.68M Offering amount: $2.68M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 9, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 17, 2010 | Initial | $2,675,263 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-146539
No cash proceeds will be received by the issuer. The total offering amount was 1,677,386.14 GBP. Using the August 9, 2010 Interbank exchange rate, the total offering amount is equal to $2,675,263.155.
Source: Form D, filed Aug 17, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony David Baxter | Director, Executive |
| John Kevin Dootson | Director, Executive |
| Ralph Stephen Harris | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Barbirolli Square
Manchester, X0, M2 3AB
Manchester, X0, M2 3AB